Mosby's 2014 Nursing Drug Reference (139 page)

HIGH ALERT
DOPamine (Rx)

(doe′pa-meen)

Func. class.:
Adrenergic

Chem. class.:
Catecholamine

Do not confuse:
DOPamine
/DOBUTamine

ACTION:

Causes increased cardiac output; acts on β
1
- and α-receptors, causing vasoconstriction in blood vessels; low dose causes renal and mesenteric vasodilation; β
1
stimulation produces inotropic effects with increased cardiac output

USES:

Shock, increased perfusion, hypotension, cardiogenic/septic shock

Unlabeled uses:
Bradycardia, cardiac arrest, CPR, acute renal failure, cirrhosis, barbiturate intoxication

CONTRAINDICATIONS:

Hypersensitivity, ventricular fibrillation, tachydysrhythmias, pheochromocytoma, hypovolemia

Precautions:
Pregnancy (C), breastfeeding, geriatric patients, arterial embolism, peripheral vascular disease, sulfite hypersensitivity, acute MI

 

Black Box Warning:

Extravasation

DOSAGE AND ROUTES
Calculator
Shock


Adult: IV INF
2-5 mcg/kg/min, titrate upward in 5-10 mcg/kg/min increments, max 50 mcg/kg/min; titrate to patient’s response

• Child: IV
1-5 mcg/kg/min initially; usual dosage range, 2-20 mcg/kg/min

COPD


Adult: IV
4 mcg/kg/min

CHF


Adult: IV
3-10 mcg/kg/min

Bradycardia (unlabeled)


Adult: IV
2-10 mcg/kg/min, titrate as needed

Available forms:
Inj 40 mg, 80 mg, 160 mg/ml; conc for IV inf 0.8, 1.6, 3.2 mg/ml in 250, 500 ml D
5
W

Administer:
IV route

• 
IV after diluting 200-400 mg/250-500 ml of D
5
W, D
5
0.45% NaCl, D
5
0.9% NaCl, D
5
LR, LR; use large vein

• 
After reconstituting, use inf pump; give at rate of 0.5-5 mcg/kg/min, increase by 1-4 mcg/kg/min at 10-30 min intervals until desired response

 

Black Box Warning:

Extravasation:
if extravasation occurs, stop infusion, may inject area with phentolamine 10 mg/15 ml of NS

Y-site compatibilities:
Alfentanil, alprostadil, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, anidulafungin, argatroban, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefamandole, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefpirome, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clarithromycin, clindamycin, cloNIDine, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, foscarnet, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methicillin, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, micanfungin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins injection, mycophenolate, nafcillin, nalbuphine, naloxone, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pen
tazocine, PENTobarbital, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate, succinylcholine, SUFentanil, tacrolimus, temocillin, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex/C, voriconazole, warfarin, zidovudine, zoledronic acid

SIDE EFFECTS

CNS:
Headache
, anxiety

CV:
Palpitations
,
tachycardia,
hypertension, ectopic beats, angina
,
wide QRS complex,
peripheral vasoconstriction, hypotension

GI:
Nausea, vomiting, diarrhea

INTEG:
Necrosis, tissue sloughing with extravasation, gangrene

RESP:
Dyspnea

PHARMACOKINETICS

IV:
Onset 5 min; duration <10 min; metabolized in liver, kidney, plasma; excreted in urine (metabolites); half-life 2 min

INTERACTIONS


 
Do not use within 2 wk of MAOIs; hypertensive crisis may result

Increase:
bradycardia, hypotension—phenytoin

Increase:
dysrhythmias—general anesthetics

Increase:
severe hypertension—ergots

Increase:
B/P—oxytocics

Increase:
pressor effect—tricyclics, MAOIs

Decrease:
DOPamine action—β-/α-blockers

Drug/Lab Test

Increase:
urinary catecholamine, serum glucose

NURSING CONSIDERATIONS
Assess:

• 
Hypovolemia; if present, correct first


 
Oxygenation/perfusion deficit:
check B/P, chest pain, dizziness, loss of consciousness


 
Heart failure:
S
3
gallop, dyspnea, neck venous distention, bibasilar crackles in patients with CHF, cardiomyopathy, palpate peripheral pulses

• 
I&O ratio: if urine output decreases without decrease in B/P, product may need to be reduced


 
ECG
during administration continuously; if B/P increases, product should be decreased; PCWP, CVP during inf

• 
B/P, pulse q5min

• 
Paresthesias and coldness of extremities; peripheral blood flow may decrease


 
Inj site: tissue sloughing; if this occurs, administer phentolamine mixed with NS

Perform/provide:

• 
Storage of reconstituted sol for up to 24 hr if refrigerated

• 
Do not use discolored sol; protect from light

Evaluate:

• 
Therapeutic response: increased B/P with stabilization; increased urine output

Teach patient/family:

• 
About the reason for product administration

TREATMENT OF OVERDOSE:

Discontinue IV, may give a short-acting α-adrenergic blocker

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

doripenem (Rx)

(dore-i-pen′em)

Doribax

Func. class.:
Antiinfective—miscellaneous

Chem. class.:
Carbapenem

ACTION:

Bactericidal; interferes with cell-wall replication of susceptible organisms; osmotically unstable cell wall swells, bursts from osmotic pressure

USES:

Serious infections caused by
Acinetobacter baumannii, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Escherichia coli, Klebsiella pneumoniae, Peptostreptococcus micros, Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus constellatus, Streptococcus intermedius
; complicated urinary tract infections, pyelonephritis, complicated intraabdominal infections

CONTRAINDICATIONS:

Hypersensitivity to carbapenems (meropenem, doripenem, imipenem), penicillin, β-lactam; viral infection

Precautions:
Pregnancy (B), breastfeeding, geriatric patients, renal disease, seizure disorder, pseudomembranous colitis, nebulizer or inhalation use

DOSAGE AND ROUTES
Calculator


Adult: IV
500 mg q8hr × 5-14 days; if improvement occurs after 3 days, switch to appropriate oral product

Renal dose


 
Adult: IV
CCr 30-50 ml/min, 250 mg over 1 hr, q8hr; CCr >10 to <30 ml/min, 250 mg over 1 hr q12hr; CCr ≤10 ml/min, no data

Available forms:
Powder for inj 250, 500 mg

Administer:
IV route

• 
Visually inspect parenteral products for particulate matter and discoloration before use, diluted range in color from clear, colorless solutions to solutions that are clear and slightly yellow

• 
Reconstitution:
No bacteriostatic preservative is present; observe aseptic technique while preparing the infusion

• 
500-mg dose using the 500-mg vial
: Constitute the vial with 10 ml of sterile water for injection or sodium chloride 0.9% (normal saline). Gently shake (50 mg/ml);
the constituted suspension is not for direct injection; further dilution is required.
Using a syringe with a 21-G needle, withdraw the suspension and add it to an infusion bag containing 100 ml of NS or D
5
W; gently shake until clear: final concentration: 4.5 mg/ml

• 
250-mg dose using the 500 mg vial
: Constitute the vial with 10 ml of sterile water for injection or sodium chloride 0.9% (normal saline). Gently shake (50 mg/ml);
the constituted suspension is not for direct injection; further dilution is required.
Using a syringe with a 21-G needle, withdraw the suspension and add it to an infusion bag containing 100 ml of normal saline or D
5
W; gently shake until clear; remove 55 ml of this solution and discard. The remaining inf sol contains 250 mg (4.5 mg/ml)

• 
250-mg dose using the 250 mg vial
: Constitute the vial with 10 ml of sterile water for injection or sodium chloride 0.9% (normal saline). Gently shake (25 mg/ml);
the constituted suspension is not for direct injection; further dilution is required.
Using a syringe with a 21-G needle, withdraw the suspension and add it to an infusion bag containing 50 or 100 ml of normal saline or D
5
W; gently shake until clear; final concentration 4.2 mg/ml (50 ml infusion bag) or 2.3 mg/ml (100 ml infusion bag)

• 
Storage:
Constituted suspensions may be held in vial for up to 1 hr before
transfer and dilution in the infusion bag. Including storage and infusion time, diluted infusion sols are stable for up to 12 hr (NS) or 4 hr (D
5
W) at controlled room temperature; diluted infusion sols are stable for up to 72 hr (NS) or 24 hr (D
5
W) refrigerated, do not freeze constituted solutions.

• 
If Baxter Minibag Plus inf bags are to be used, consult the instructions provided by the inf bag manufacturer

Intermittent IV INF route

• 
After C&S is taken

• 
Do not mix with or physically add to solutions containing other drugs, infuse over 1 hr

Y-site compatibilities:
Acyclovir, amikacin, aminophylline, amiodarone, anidulafungin, atropine, azithromycin, bumetanide, calcium gluconate, CARBOplatin, caspofungin, ceftobiprole, cimetidine, ciprofloxacin, CISplatin, cyclophosphamide, cycloSPORINE, DAPTOmycin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, DOXOrubicin, enalaprilat, esmolol, esomeprazole, etoposide, famotidine, fentaNYL, fluconazole, fluorouracil, foscarnet, furosemide, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, insulin (regular), labetalol, levofloxacin, linezolid, LORazepam, magnesium sulfate, mannitol, meperidine, methotrexate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, micafungin, midazolam, milrinone, morphine, moxifloxacin, norepinephrine, ondansetron, PACLitaxel, pantoprazole, PHENobarbital, phenylephrine, potassium chloride, ranitidine, sodium bicarbonate/phosphates, tacrolimus, tigecycline, tobramycin, vancomycin, voriconazole, zidovudine

Solution compatibilities:
D
5
W, 0.9% NaCl, sterile water for inj

SIDE EFFECTS

CNS:
Seizures,
headache

GI:
Diarrhea, nausea, vomiting,
pseudomembranous colitis, hepatitis

HEMA:
Neutropenia, leukopenia, anemia

INTEG:
Rash
, urticaria, phlebitis, erythema at inj site,
Stevens-Johnson syndrome, toxic epidermal necrolysis,
pruritus

SYST:
Anaphylaxis

PHARMACOKINETICS

IV:
Distributed to most body fluids/tissue, excreted mainly unchanged in urine, 70% recovered in 48 hr, half-life 1 hr, half-life extended in renal disease

INTERACTIONS

Increase:
doripenem plasma levels—probenecid

Decrease:
effect of valproic acid, divalproex sodium

Drug/Lab Test

Increase:
AST, ALT, LDH, BUN, alk phos, bilirubin, creatinine

False positive:
direct Coombs’ test

NURSING CONSIDERATIONS
Assess:


 
Sensitivity to carbapenem antibiotics, penicillins

• 
Renal disease: lower dose may be required

• 
Bowel pattern daily; if severe diarrhea occurs, product should be discontinued; may indicate pseudomembranous colitis

• 
For infection: temp; sputum; characteristics of wound before, during, and after treatment

 
Allergic reactions, anaphylaxis:
rash, urticaria, pruritus; may occur few days after therapy begins


 
Overgrowth of infection:
perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum

Evaluate:

• 
Therapeutic response: negative C&S; absence of symptoms and signs of infection

Teach patient/family:


 
To report severe diarrhea; may indicate pseudomembranous colitis


 
To report sore throat, bruising, bleeding, joint pain; may indicate blood dyscrasias (rare)


 
To report overgrowth of infection: black, furry tongue; vaginal itching; foul-smelling stools

• 
To avoid breastfeeding; product is excreted in breast milk

TREATMENT OF HYPERSENSITIVITY:

EPINEPHrine, antihistamines; resuscitate if needed (anaphylaxis)

Other books

WWW 2: Watch by Robert J Sawyer
Nomads of Gor by John Norman
Agent Garbo by Stephan Talty
Death by Sarcasm by Dani Amore
Chocolate Cake for Breakfast by Danielle Hawkins
Breaking Abigail by Emily Tilton
Something Light by Margery Sharp
Confirmación by Aurora Seldon e Isla Marín